CytomX Therapeutics (CTMX) Closes 7.67M Common Stock IPO at $12/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
CytomX Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
October 14, 2015 3:01 PM EDTSOUTH SAN FRANCISCO, Calif., Oct. 14, 2015 /PRNewswire/ -- CytomX Therapeutics, Inc. (Nasdaq: CTMX) (the "Company"), a biopharmaceutical company developing Probody therapeutics for the treatment of cancer, today announced the closing of its initial public offering of 7,666,667 shares of common stock at an initial public offering price of $12.00 per share, before underwriting discounts and commissions, which includes the exercise in full by the underwriters of their option to purchase up to 1,000,000 additional shares... More
